Research
Hormonal
GLP-1RA therapy can reduce the risk of cardiovascular disease (CVD) in high-risk individuals with type 2 diabetes (T2D).
Practitioners should consider GLP-1RA therapy for patients with T2D who are at high risk for cardiovascular disease.
StrongSupportsmedium confidence
Large-scale randomized controlled cardiovascular (CV) outcome trials (CVOTs) have shown that GLP-1RA therapy can reduce the risk of CV disease (CVD) in high-risk individuals with T2D.
Why this rating
Based on large-scale randomized controlled trials.
Source
Understanding the place for <scp>GLP‐1RA</scp> therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
Christine R. Andreasen et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14500
reviewCited 36×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →